Expertise in
8
conditions

Dr. Muna Qayed

Hematology | Oncology
Egleston Children's Hospital At Emory
1405 Clifton Rd NE, 
Atlanta, GA 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Egleston Children's Hospital At Emory
1405 Clifton Rd NE, 
Atlanta, GA 

Overview

Muna Qayed is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia.

Dr. Qayed is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Leukemia, Thrombocytopenia, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 144 peer reviewed articles and participating in 13 clinical trials. Dr. Qayed is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in GA

Languages Spoken

English
Arabic
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Egleston Children's Hospital at Emory
1405 Clifton Rd NE, Atlanta, GA 30322

Additional Areas of Focus

Dr. Qayed has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children With GVHD
Enrollment Status: Completed
Publish Date: June 03, 2026
Intervention Type: Drug
Study Drug: Prednisone
Study Phase: Phase 2
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease After Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies and Myelodysplasia
Enrollment Status: Terminated
Publish Date: February 13, 2026
Intervention Type: Drug
Study Drug: Interferon gamma-primed human bone marrow-derived mesenchymal stromal cells
Study Phase: Phase 1
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Drug
Study Drug: Abatacept
Study Phase: Phase 2
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2025
Intervention Type: Biological
Study Drug: Virus Specific T-cell infusion
Study Phase: Phase 1/Phase 2
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: June 20, 2024
Intervention Type: Drug, Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 2
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
Enrollment Status: Unknown
Publish Date: February 08, 2023
View 9 Less Clinical Trials

144 Total Publications

MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.
MAGIC Composite Score Predicts Outcomes of Second-Line Therapy for Acute GVHD.
Journal: medRxiv : the preprint server for health sciences
Published: July 29, 2026
Similar Doctors
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Expertise in
5
conditions
Dr. Carlton D. Dampier
Hematology | Oncology
Referral may be required

Children's Healthcare Of Atlanta At Hughes Spalding

35 Jesse Hill Jr Dr SE, 
Atlanta, GA 
 (4.5 miles away)
404-785-9800
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Carlton Dampier is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Dampier is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia. Dr. Dampier is currently accepting new patients.

Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Expertise in
9
conditions
Dr. Lakshmanan Krishnamurti
Hematology | Oncology
Referral may be required

Egleston Children's Hospital At Emory

1405 Clifton Rd NE, 
Atlanta, GA 
 (0.1 miles away)
404-785-1112
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Lakshmanan Krishnamurti is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Krishnamurti is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant. Dr. Krishnamurti is currently accepting new patients.

Expertise in
9
conditions
Dr. Tobey J. Macdonald
Hematology | Oncology
Expertise in
9
conditions
Dr. Tobey J. Macdonald
Hematology | Oncology
Referral may be required

Office

1760 Haygood Dr NE, 
Atlanta, GA 
 (0.2 miles away)
404-785-1112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Tobey Macdonald is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. Dr. Macdonald is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Medulloblastoma, Brain Tumor, Posterior Fossa Tumor, and Embryonal Tumor with Multilayered Rosettes. Dr. Macdonald is currently accepting new patients.

Frequently Asked Questions about Dr. Muna Qayed

How do I make an appointment with Dr. Muna Qayed?

You can book an appointment with Dr. Muna Qayed by calling their office at 404-785-1200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Muna Qayed a top-rated expert for Graft Versus Host Disease (GvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Muna Qayed is classified as an Elite expert for Graft Versus Host Disease (GvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Muna Qayed specialize in?

While Dr. Muna Qayed is a Hematology, they have specific expertise in Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplant. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Muna Qayed participate in research or clinical trials?

Yes. Dr. Muna Qayed has published 144 articles and abstracts on conditions like Graft Versus Host Disease (GvHD). You can view a list of Dr. Muna Qayed's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Muna Qayed accept my insurance?

Dr. Muna Qayed accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 404-785-1200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Qayed's expertise for a condition
ConditionClose
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile